Literature DB >> 9518049

Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue.

S G Gordon1, W P Mielicki.   

Abstract

Hemostatic abnormalities associated with malignant disease led to the search for and discovery of a proteolytic enzyme that activated factor X in the blood coagulation cascade. It was named cancer procoagulant (CP). CP is a cysteine proteinase that is found in malignant and fetal (human amnion-chorion) tissue; it has not been found in normally differentiated tissue. It is a calcium-dependent, Mn2+ stimulated enzyme that has enhanced activity and inhibition in a reduced environment. This review presents a complete compilation and discussion of the known chemical and enzymatic characteristics of CP as well as many purification and assay procedures. Several unique properties of these procedures are described. Some problems and controversies are highlighted in each of the sections. An immunoassay for CP as a tumor marker and some of its potential applications in the diagnosis and monitoring of cancer are reviewed. Some therapeutic implications of CP are noted in light of the observation that antibodies to CP block the metastatic seeding of lung colonies in vivo and diminish the viability of tumor cells in vitro. Finally, comments about the relationship between tissue factor and CP in the malignant cells are provided.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9518049

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  11 in total

1.  A 52-year-old-male patient with metastatic non-small-cell lung cancer and recurrent venous thromboembolism in unusual sites despite anticoagulation.

Authors:  Alexios Matikas; Nikolaos Vardakis; John Souglakos; Vassilios Georgoulias
Journal:  BMJ Case Rep       Date:  2013-09-17

2.  Rat prostate tumors express cancer procoagulant, an activator of coagulation factor X.

Authors:  Malgorzata Kamocka; Morris Pollard; Mark Suckow; Wojciech P Mielicki; Elliot D Rosen
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

3.  In Vitro Screening of Synthetic Fluorogenic Substrates for Detection of Cancer Procoagulant Activity.

Authors:  Jason Krause; Carminita L Frost
Journal:  Protein J       Date:  2018-04       Impact factor: 2.371

4.  The proteolytic profile of human cancer procoagulant suggests that it promotes cancer metastasis at the level of activation rather than degradation.

Authors:  Nalise Low Ah Kee; Jason Krause; Gregory L Blatch; Koji Muramoto; Kazuo Sakka; Makiko Sakka; Ryno J Naudé; Leona Wagner; Raik Wolf; Jens-Ulrich Rahfeld; Hans-Ulrich Demuth; Wojciech P Mielicki; Carminita L Frost
Journal:  Protein J       Date:  2015-10       Impact factor: 2.371

5.  [Tissue factors and venous thromboembolism in cancer patients].

Authors:  Huiqi Zhu; Kejing Ying
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-25

6.  Non-bacterial thrombotic endocarditis manifested by ventricular fibrillation in a patient with low grade ovarian carcinoma: case report and literature review.

Authors:  Remko S Kuipers; Meike A T Berghuis; Aernout C Ogilvie; Sanne A van Wissen; Robert K Riezebos
Journal:  Eur Heart J Case Rep       Date:  2021-04-21

Review 7.  Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.

Authors:  T E Clark; N Edom; J Larson; L J Lindsey
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

8.  Arterial and venous thrombosis in cancer patients.

Authors:  Andrew D Blann; Simon Dunmore
Journal:  Cardiol Res Pract       Date:  2011-03-03       Impact factor: 1.866

9.  Ventricular metastasis resulting in disseminated intravascular coagulation.

Authors:  Thomas John; Ian D Davis
Journal:  World J Surg Oncol       Date:  2005-05-24       Impact factor: 2.754

10.  Acute disseminated intravascular coagulation following surgical resection of a myeloid sarcoma in a 57-year-old male.

Authors:  Rohan Paul; David Morgan; Michael Levitt; Ross Baker
Journal:  Clin Pract       Date:  2012-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.